Effects of cytochrome P450 (CYP3A4 and CYP2C19) inhibition and induction on the exposure of selumetinib, a MEK1/2 inhibitor, in healthy subjects: results from two clinical trials
Crossref DOI link: https://doi.org/10.1007/s00228-016-2153-7
Published Online: 2016-11-26
Published Print: 2017-02
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Dymond, Angela W.
So, Karen
Martin, Paul
Huang, Yifan
Severin, Paul
Mathews, David
Lisbon, Eleanor
Mariani, Gabriella
Funding for this research was provided by:
AstraZeneca (None)
License valid from 2016-11-26